# A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct06667908/  
OnCo record `nct06667908` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of JNJ-90301900, Durvalumab and Carboplatin in non-small-cell lung cancer, run by Johnson & Johnson Enterprise Innovation Inc., now recruiting.

## Summary

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06667908 by Johnson & Johnson Enterprise Innovation Inc., with 130 participants planned, started 2024-12-06 and due to reach its primary completion in 2028-12-31. Interventions recorded: JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin and Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06667908
- Phase: 2
- Setting: A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC
- Sponsor: Johnson & Johnson Enterprise Innovation Inc.
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT06667908: https://clinicaltrials.gov/study/NCT06667908

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [JNJ-90301900](https://onco.cc/drugs/jnj-90301900/)

---
JSON: https://onco.cc/api/v1/entities/nct06667908.json